KAYSERI from Turkey
Turkey administered the second dose to volunteers on Wednesday as part of ongoing trials for the country’s local COVID-19 vaccine candidate, ERUCOV-VAC.
Phase 2 trials are being conducted by Erciyes University in the central province of Kayseri.
37-year-old volunteer Soner Akel, who was given the second dose, said he did not experience any side effects.
University director Mustafa Calis has said he wants to finalize phase 2 trials by mid-April.
“Phase 2 studies of our locally developed vaccine are ongoing. Today we administered the second dose to our volunteers,” Calis said.
On January 14, Turkey launched a mass vaccination campaign against COVID-19 starting with health workers.
Since its emergence in December 2019, the virus has killed more than 2.6 million people in 192 countries and regions.
More than 117.6 million cases have been reported worldwide, with recoveries totaling more than 66.6 million, according to figures compiled by Johns Hopkins University.
The United States, India and Brazil remain the most affected countries in terms of infections.
The Anadolu Agency website contains only a portion of the stories offered to subscribers in the AA News Distribution System (HAS), and in summary form. Please contact us for subscription options.